Skip to content
18 November · 06:30 UTCFollow GSK by emailFollow

GSK · Pharma and healthcare · one day

GSK (GSK): news on Wednesday 18 November 2026

News from the 24 hours to Wednesday morning, 18 November 2026.

Tone of the day

+7.5strongly positive
Relevant headlines36of 38 read
Stories6grouped by event

What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Why it scored this way

Most coverage focused on US approval of Nelkarmi, the second lung cancer medicine to come from the Nuvalent acquisition, which advances its oncology push. A few items on patent expiry concerns, job cuts and a small share price dip moderated the tone.

What drove it

  • Nelkarmi FDA approval
  • oncology growth plan
  • patent cliff concerns

Around this day

DayToneHeadlines
Thu 12 Nov+4.512
Fri 13 Nov+4.214
Sat 14 Nov+9.220
Sun 15 Nov+7.06
Mon 16 Nov+2.54
Tue 17 Nov+5.78
Wed 18 Nov+7.536

6 stories · 36 headlines · strongest first

Pharma and healthcare on 18 NovemberFTSE 100 that day
ToneWhat the article reported, and why it scored that waySource
Nelkarmi receives US accelerated approval for ALK-positive lung cancer +9.522 headlines today · Outlets report that Nelkarmi (neladalkib), the second lung cancer medicine GSK has gained from buying Nuvalent, received accelerated US approval.
+10.0Approved drug seen as having very large sales potential.Bloomberg (opens the article) ↗
+10.0Second product from major acquisition gains US clearance.Reuters (opens the article) ↗
+10.0Second approval from large acquisition supports its value.FT Companies (opens the article) ↗
+10.0Second approval from large acquisition supports its value.FT Companies (opens the article) ↗
+10.0Second acquired lung cancer drug clears regulator.Fierce Pharma (opens the article) ↗
+10.0Regulatory clearance for second cancer medicine from acquired portfolio.PRESS Insider (opens the article) ↗
+10.0Approval bolsters its growing cancer franchise.Traders Union (opens the article) ↗
+10.0Approval from major deal adds to oncology line-up.TradingView (opens the article) ↗
+9.7Acquisition delivers another marketed oncology product.FirstWord Pharma (opens the article) ↗
+9.7Second lung cancer product cleared following acquisition.Quartz (opens the article) ↗
+9.5Regulator clears therapy gained through takeover.Seeking Alpha (opens the article) ↗
+9.5US regulator clears new lung cancer medicine.grafa.com (opens the article) ↗
+9.2Accelerated US clearance for new lung cancer treatment.London South East (opens the article) ↗
+9.2Approval for previously treated ALK-positive patients.Investing.com (opens the article) ↗
+9.2US regulator approves its lung cancer medicine.Investing.com (opens the article) ↗
+9.2Company announces US approval for advanced lung cancer treatment.Yahoo Finance (opens the article) ↗
+9.0Approval addresses resistance in a lung cancer subtype.GenomeWeb (opens the article) ↗
+8.7Conditional US clearance for lung cancer drug.TradingView (opens the article) ↗
+8.7Conditional US clearance for lung cancer drug.StreetInsider (opens the article) ↗
+8.7Conditional US approval for lung cancer drug.tokenpost.com (opens the article) ↗
+8.3US regulators clear its cancer medicine.Financial Times (opens the article) ↗
+8.3Brief report of US regulatory clearance.Breakingthenews.net (opens the article) ↗
GSK presents growth plan at Jefferies healthcare conference +0.77 headlines today · Coverage of GSK's conference presentation covers its 2031 sales ambition, savings, Phase III starts and the HIV patent cliff.
+8.3Cost savings and pipeline starts underpin ambitious long-term sales goal.TradingView (opens the article) ↗
+5.8Management says growth plan is accelerating.Investing.com India (opens the article) ↗
−5.0Job cuts and restructuring raise pressure on shares.Traders Union (opens the article) ↗
−5.0Concern over expiring patents despite oncology plans.AD HOC NEWS (opens the article) ↗
+3.3Finance chief relies on oncology to offset forecast shortfall.Yahoo Finance (opens the article) ↗
−1.7Growth plan discussed alongside patent expiry challenge.Investing.com (opens the article) ↗
−0.8Ambitious sales target tempered by HIV patent expiry concerns.TradingView (opens the article) ↗
GSK share outlook and market commentary +0.53 headlines today · 7 in all, since 17 November · Pieces report small share-price falls and discuss whether to sell GSK shares.
−3.3Shares dipped despite decent quarterly performance.Traders Union (opens the article) ↗
−1.7Small premarket share price decline.AD HOC NEWS (opens the article) ↗
−0.8Adviser question about selling holdings; neutral commentary.Investors' Chronicle (opens the article) ↗
Jefferies keeps Neutral rating on GSK +0.42 headlines today · Jefferies reaffirmed its Neutral rating, with some profit-taking in the shares noted.
+0.8Shares eased as investors banked gains despite supportive broker.MarketScreener (opens the article) ↗
0.0Broker keeps middling view unchanged.MarketScreener (opens the article) ↗
EU committee backs GSK's Bexsero meningitis B booster +9.21 headline today · 14 in all, since 14 November · A piece asks whether Bexsero can extend its reach after the CHMP recommendation.
+6.7European committee backs booster for meningitis vaccine.Kalkine Media (opens the article) ↗
GSK executive share purchases +2.71 headline today · 2 in all, since 14 November · A director and executives acquired ADSs through dividend reinvestment.
+0.3Routine insider share acquisition via dividend reinvestment.TipRanks (opens the article) ↗

Each article has its own score. The lines are our own summary; follow the source link to read the article itself.

Follow by email

A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 18 November · 867 headlines · 94 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt